

Revealing Vitamin D Pathways to Prostate Cancer Prevention and Treatment

Posted September 14, 2010

Nancy L. Weigel, Ph.D., Baylor College of Medicine, Houston, Texas




Supported by Fiscal Year 2003 (FY03) and FY08 PCRP Idea Development Awards, Dr. Nancy Weigel is discovering the mechanisms by which vitamin D, well-recognized to inhibit growth of prostate cancer cells in culture and in some animal tumor models, can best be exploited for prostate cancer prevention and treatment.

Higher exposure to sunlight (the major contributor to vitamin D production in the body) correlates with decreased risk for prostate cancer. Phase II/III clinical trials are already in progress to test the potential of vitamin D and its derivatives to prevent or delay the progression of early- and late-stage prostate cancer. Although the precise mechanisms through which vitamin D inhibits prostate cancer growth are still unclear, it has been shown that the active metabolite of vitamin D, 1,25-dihydroxyvitamin D₃(1,25D), and a highly potent analog, EB1089 (seocalcitol), bind the vitamin D receptor (VDR) in cells and subsequently turn on the expression of genes that inhibit prostate cancer cell growth. A better understanding of specific changes in gene expression and their role in prostate cancer development will provide insight toward maximizing the efficacy of vitamin D in preventing and treating the disease.

With her PCRP funding, Dr. Weigel sought to specifically identify the genes regulated by vitamin D in both normal and cancerous prostate cells. One of the genes whose expression was suppressed in non-transformed (RWPE-1), androgen-dependent (LNCaP and LAPC-4), and androgen-independent (C4-2) prostate cancer cells was c-Myc, an oncogenic transcription factor frequently overexpressed in prostate cancer. Using small inhibitory RNA (siRNA) knockdown experiments of c-Myc expression in C4-2 cells, Dr. Weigel showed that the reduction in c-Myc expression by siRNA treatment was similar to that observed with 1,25D treatment. In both 1,25D and siRNA-treated cells, there was a comparable decrease in cell proliferation. Using androgen-dependent prostate cancer cells (LNCaP and LAPC-4) treated with or without EB1089, she showed that about 25 genes were upregulated and 7 genes were downregulated by EB1089 in both cell lines. One of the upregulated genes was TMPRSS2. As this androgen regulated gene plays a role in the TMPRSS2-ETS gene fusions found in over 50% of prostate tumors and is associated with more aggressive disease, Dr. Weigel examined the effect of 1,25D on the TMPRSS2-ERG fusion gene

present in the androgen-dependent prostate cancer cell line VCaP. She found that 1,25D and EB1089 both increased the expression of the TMPRSS2-ERG fusion gene, but reduced the growth and proliferation of VCaP cells. Furthermore, vitamin D decreased the expression of c-Myc, a TMPRSS2-ERG target gene and transcription factor that is overexpressed in a variety of cancers and is a critical component for cell proliferation. Thus, 1,25D may be beneficial in prostate cancers that express the TMPRSS2-ETS gene fusions, but additional studies including studies *in vivo* are needed.

Dr. Weigel, a dedicated teacher who has also received FY05 and FY08 PCRP Collaborative Undergraduate Historically Black Colleges and Universities Student Summer Training Program Awards, directs the Prairie View A & M/Baylor College of Medicine SMART Summer Undergraduate Prostate Cancer Research Project, which is a 9-week summer prostate cancer research experience designed to encourage minority college students to pursue careers in biomedical science.



*The vitamin D receptor (VDR) induces TMPRSS2:ERG expression, but down-regulates c-Myc, an ERG target. The TMPRSS2:ETS factor fusions, present in greater than 50% of prostate cancers, stimulate motility, invasiveness, and cell and tumor growth. Dr. Weigel's research team's finding that VDR induces TMPRSS2 led them to test the response of VCaP cells expressing the TMPRSS2:ERG fusion to VDR activation. Treatment with the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, induced TMPRSS2:ERG, but reduced cell growth and expression of c-Myc, an ERG target gene in this cell line. Whether there are additional actions of 1,25-dihydroxyvitamin D3 that counteract ERG stimulated motility, invasiveness, and growth of tumors *in vivo* remains to be determined.*

Publication:

Rohan JN and Weigel NL. 2009. 1alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. *Endocrinology* 150(5):2046-54.

Washington MC and Weigel NL. 2010. 1alpha,25-dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth promoting TMPRSS2:ERG gene fusion. *Endocrinology* 151(4):1409-1417.

Links:

[Public and Technical Abstracts: TMPRSS2-ERG Gene Fusions and Vitamin D Action in Prostate Cancer](#)

[Public and Technical Abstracts: Prairie View A&M/Baylor College of Medicine SMART Summer Undergraduate Prostate Cancer Research Project](#)

[Public and Technical Abstracts: Prairie View A & M/Baylor College of Medicine SMART Summer Undergraduate Prostate Cancer Research Project](#)

[Public and Technical Abstracts: Vitamin D Receptor Target Genes as Predictors of Responsiveness to Treatment with a Vitamin D Receptor](#)

NANCY WEIGEL

Title Professor

Institution Baylor College of Medicine

Department Department of Molecular & Cellular Biology

Division Molecular & Cellular Biology

Email

vCard Download vCard

Other Positions

Title Professor

Institution Baylor College of Medicine

Department Department of Urology

Division Urology

ORNG Applications

Verify Publications

Research

research activities and funding

R01HD022061 (WEIGEL, NANCY LYNN)Jul 1, 1986 - Jun 30, 1995

NIH/NICHD

REGULATION OF PROGESTERONE RECEPTORS BY PHOSPHORYLATION

Role: Principal Investigator

R55CA057539 (WEIGEL, NANCY LYNN)Sep 30, 1992 - Mar 31, 1993

NIH/NCI

REGULATION OF HUMAN STEROID RECEPTORS BY PHOSPHORYLATION

Role: Principal Investigator

R01CA057539 (WEIGEL, NANCY L)Apr 15, 1993 - Mar 31, 2006

NIH/NCI

Regulation of Human Steroid Receptors by Phosphorylation

Role: Principal Investigator

R01CA075337 (WEIGEL, NANCY LYNN)Dec 24, 1998 - Nov 30, 2004

NIH/NCI

INHIBITION OF PROSTATE CANCER CELL GROWTH BY VITAMIN D

Role: Principal Investigator

R01DK065252 (WEIGEL, NANCY LYNN)Aug 1, 2003 - May 31, 2008

NIH/NIDDK

Coactivators and Androgen Receptors in Prostate Cancer

Role: Principal Investigator

R01CA107691 (WEIGEL, NANCY LYNN)Jun 2, 2004 - May 31, 2009

NIH/NCI

Targets of Vitamin D Receptor Action in Prostate

Role: Principal Investigator

R13CA112924 (WEIGEL, NANCY LYNN)Feb 18, 2005 - Jan 31, 2006

NIH/NCI

Conference on Hormonal Regulation of Tumorigenesis

Role: Principal Investigator

Bibliographic

selected publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can [login](#) to make corrections and additions.

List All | Timeline

1. Zhang M, Suarez E, Vasquez JL, Nathanson L, Peterson LE, Rajapakshe K, Basil P, Weigel NL, Coarfa C, Agoulnik IU. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. *Oncogene*. 2019 02; 38(7):1121-1135. PMID: 30228349.

View in: [PubMed](#)

2. Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, Wells C, Lee S, Zuehlke AD, Shao H, Bingman WE, Kumar V, Malhotra SV, Weigel NL, Gestwicki JE, Trepel JB, Neckers LM. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. *Cancer Res*. 2018 07 15; 78(14):4022-4035. PMID: 29764864.

View in: [PubMed](#)

3. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. *Eur Urol*. 2018 05; 73(5):715-723. PMID: 29258679.

View in: [PubMed](#)

4. Roberts JM, Martin RS, Piyarathna DB, MacKrell JG, Rocha GV, Dodge JA, Coarfa C, Krishnan V, Rowley DR, Weigel NL. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. *Oncotarget*. 2017 Jul 04; 8(27):44447-44464. PMID: 28591703.

View in: [PubMed](#)

5. Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. *Nat Commun*. 2016 05 19; 7:11612. PMID: 27194471.

View in: [PubMed](#)

6. Lopez SM, Agoulnik AI, Zhang M, Peterson LE, Suarez E, Gandarillas GA, Frolov A, Li R, Rajapakshe K, Coarfa C, Ittmann MM, Weigel NL, Agoulnik IU. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. *Clin Cancer Res.* 2016 08 01; 22(15):3937-49. PMID: 26968201.

View in: [PubMed](#)

7. Treviño LS, Bolt MJ, Grimm SL, Edwards DP, Mancini MA, Weigel NL. Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. *Mol Endocrinol.* 2016 Feb; 30(2):158-72. PMID: 26652902.

View in: [PubMed](#)

8. Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. *Oncotarget.* 2015 Oct 13; 6(31):31997-2012. PMID: 26378018.

View in: [PubMed](#)

9. Weigel NL. Hormones and Cancer--Looking Forward. *Horm Cancer.* 2015 Dec; 6(5-6):189-90. PMID: 26305704.

View in: [PubMed](#)

10. Weigel NL. Hormones and Cancer: an exciting young journal for an expanding field of basic, translational, and clinical study. *Horm Cancer.* 2015 Jun; 6(2-3):65-6. PMID: 25869229.

View in: [PubMed](#)

11. He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. *Proc Natl Acad Sci U S A.* 2014 Dec 23; 111(51):18261-6. PMID: 25489091.

View in: [PubMed](#)

12. Grimm SL, Ward RD, Obr AE, Franco HL, Fernandez-Valdivia R, Kim JS, Roberts JM, Jeong JW, DeMayo FJ, Lydon JP, Edwards DP, Weigel NL. A role for site-specific phosphorylation of mouse progesterone receptor at serine 191 in vivo. *Mol Endocrinol.* 2014 Dec; 28(12):2025-37. PMID: 25333515.

View in: [PubMed](#)

13. Moore NL, Edwards DP, Weigel NL. Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells. *J Steroid Biochem Mol Biol.* 2014 Oct; 144 Pt B:471-82. PMID: 25220500.

View in: [PubMed](#)

14. Rechoum Y, Rovito D, Iacopetta D, Barone I, Andò S, Weigel NL, O'Malley BW, Brown PH, Fuqua SA. AR collaborates with ER α in aromatase inhibitor-resistant breast cancer. *Breast Cancer Res Treat.* 2014 Oct; 147(3):473-85. PMID: 25178514.

View in: [PubMed](#)

15. Krause WC, Shafi AA, Nakka M, Weigel NL. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. *Int J Biochem Cell Biol.* 2014 Sep; 54:49-59. PMID: 25008967.

View in: [PubMed](#)

16. Kim JS, Roberts JM, Bingman WE, Shao L, Wang J, Ittmann MM, Weigel NL. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. *Endocrinology.* 2014 Sep; 155(9):3262-73. PMID: 24926821.

View in: [PubMed](#)

17. Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, Brennan CA, Chinnaiyan AM, Vergara IA, Erho N, Weigel NL, Mitsiades N, Shojaie A, Palapattu G, Michailidis G, Sreekumar A. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. *J Proteome Res.* 2014 Feb 07; 13(2):1088-100. PMID: 24359151.

View in: [PubMed](#)

18. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. *Pharmacol Ther.* 2013 Dec; 140(3):223-38. PMID: 23859952.

View in: [PubMed](#)

19. Treviño LS, Weigel NL. Phosphorylation: a fundamental regulator of steroid receptor action. *Trends Endocrinol Metab.* 2013 Oct; 24(10):515-24. PMID: 23838532.

View in: [PubMed](#)

20. Treviño LS, Bingman WE, Edwards DP, NI W. The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific. *Steroids*. 2013 Jun; 78(6):542-7. PMID: 23380370.

View in: [PubMed](#)

21. Shafi AA, Cox MB, Weigel NL. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. *Steroids*. 2013 Jun; 78(6):548-54. PMID: 23380368.

View in: [PubMed](#)

22. Nakka M, Agoulnik IU, Weigel NL. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. *Int J Biochem Cell Biol*. 2013 Apr; 45(4):763-72. PMID: 23270728.

View in: [PubMed](#)

23. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. *Int J Oncol*. 2013 Jan; 42(1):35-43. PMID: 23152004.

View in: [PubMed](#)

24. Searle NS, Teal CR, Richards BF, Friedland JA, Weigel NL, Hernandez RA, Lomax JW, Coburn M, Nelson EA. A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions process. *Acad Med*. 2012 Jul; 87(7):870-6. PMID: 22622222.

View in: [PubMed](#)

25. Moore NL, Weigel NL. Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. *Int J Biochem Cell Biol*. 2011 Aug; 43(8):1157-67. PMID: 21550420.

View in: [PubMed](#)

26. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. *Cancer Res*. 2011 Jan 15; 71(2):572-82. PMID: 21224358.

View in: [PubMed](#)

27. Washington MN, Kim JS, Weigel NL. 1a,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. *Prostate*. 2011 Jan 01; 71(1):98-110. PMID: 20632309.

View in: [PubMed](#)

28. Washington MN, Weigel NL. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. *Endocrinology*. 2010 Apr; 151(4):1409-17. PMID: 20147525.

View in: [PubMed](#)

29. Wardell SE, Narayanan R, Weigel NL, Edwards DP. Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. *Mol Endocrinol*. 2010 Feb; 24(2):335-45. PMID: 20008003.

View in: [PubMed](#)

30. Ward RD, Weigel NL. Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. *Biofactors*. 2009 Nov-Dec; 35(6):528-36. PMID: 19904813.

View in: [PubMed](#)

31. Bhatia V, Mula RV, Weigel NL, Falzon M. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. *Mol Cancer Res*. 2009 Jul; 7(7):1119-31. PMID: 19584267.

View in: [PubMed](#)

32. Bhatia V, Saini MK, Shen X, Bi LX, Qiu S, Weigel NL, Falzon M. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. *Mol Cancer Ther*. 2009 Jul; 8(7):1787-98. PMID: 19584236.

View in: [PubMed](#)

33. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. *Breast Cancer Res Treat*. 2010 May; 121(1):1-11. PMID: 19533338.

View in: [PubMed](#)

34. Agoulnik IU, Weigel NL. Coactivator selective regulation of androgen receptor activity. *Steroids*. 2009 Aug; 74(8):669-74. PMID: 19463689.

View in: [PubMed](#)

35. Rohan JN, Weigel NL. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. *Endocrinology*. 2009 May; 150(5):2046-54. PMID: 19164469.

View in: [PubMed](#)

36. Agoulnik IU, Bingman WE, Nakka M, Li W, Wang Q, Liu XS, Brown M, Weigel NL. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. *Mol Endocrinol*. 2008 Nov; 22(11):2420-32. PMID: 18787043.

View in: [PubMed](#)

37. Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. *Adv Exp Med Biol*. 2008; 617:245-55. PMID: 18497048.

View in: [PubMed](#)

38. Shen X, Mula RV, Li J, Weigel NL, Falzon M. PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3). *Steroids*. 2007 Dec; 72(14):930-8. PMID: 17904173.

View in: [PubMed](#)

39. Weigel NL. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. *Nutr Rev*. 2007 Aug; 65(8 Pt 2):S116-7. PMID: 17867385.

View in: [PubMed](#)

40. Rudd MD, Gonzalez-Robayna I, Hernandez-Gonzalez I, Weigel NL, Bingman WE, Richards JS. Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. *J Mol Endocrinol*. 2007 Jun; 38(6):673-90. PMID: 17556536.

View in: [PubMed](#)

41. Weigel NL, Moore NL. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. *Mol Endocrinol*. 2007 Oct; 21(10):2311-9. PMID: 17536004.

View in: [PubMed](#)

42. Weigel NL, Moore NL. Kinases and protein phosphorylation as regulators of steroid hormone action. *Nucl Recept Signal*. 2007 May 17; 5:e005. PMID: 17525795.

View in: [PubMed](#)

43. Weigel NL, Moore NL. Cyclins, cyclin dependent kinases, and regulation of steroid receptor action. *Mol Cell Endocrinol.* 2007 Feb; 265-266:157-61. PMID: 17207919.

View in: [PubMed](#)

44. Moore NL, Narayanan R, Weigel NL. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. *Steroids.* 2007 Feb; 72(2):202-9. PMID: 17207508.

View in: [PubMed](#)

45. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. *Pharmacol Rev.* 2006 Dec; 58(4):782-97. PMID: 17132855.

View in: [PubMed](#)

46. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. *Cancer Res.* 2006 Nov 01; 66(21):10594-602. PMID: 17079484.

View in: [PubMed](#)

47. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. *J Cell Biochem.* 2006 Oct 01; 99(2):362-72. PMID: 16619264.

View in: [PubMed](#)

48. Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. *J Cell Biochem.* 2006 Jul 01; 98(4):770-88. PMID: 16440331.

View in: [PubMed](#)

49. Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. *Biochem J.* 2006 May 01; 395(3):653-62. PMID: 16417524.

View in: [PubMed](#)

50. Proia DA, Nannenga BW, Donehower LA, Weigel NL. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. *J Biol Chem.* 2006 Mar 17; 281(11):7089-101. PMID: 16352595.

View in: [PubMed](#)

51. Sepulveda VA, Weigel NL, Falzon M. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. *Steroids.* 2006 Feb; 71(2):102-15. PMID: 16243370.

View in: [PubMed](#)

52. Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. *Cancer Res.* 2005 Sep 01; 65(17):7959-67. PMID: 16140968.

View in: [PubMed](#)

53. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. *Prostate.* 2005 Sep 01; 64(4):362-72. PMID: 15754350.

View in: [PubMed](#)

54. Stewart LV, Lyles B, Lin MF, Weigel NL. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. *J Steroid Biochem Mol Biol.* 2005 Oct; 97(1-2):37-46. PMID: 16076555.

View in: [PubMed](#)

55. Stewart LV, Weigel NL. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. *Prostate.* 2005 Jun 15; 64(1):9-19. PMID: 15651061.

View in: [PubMed](#)

56. Narayanan R, Edwards DP, Weigel NL. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. *Mol Cell Biol.* 2005 Apr; 25(8):2885-98. PMID: 15798179.

View in: [PubMed](#)

57. Srinivas H, Juroske DM, Kalyankrishna S, Cody DD, Price RE, Xu XC, Narayanan R, Weigel NL, Kurie JM. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. *Mol Cell Biol.* 2005 Feb; 25(3):1054-69. PMID: 15657432.

View in: [PubMed](#)

58. Narayanan R, Adigun AA, Edwards DP, Weigel NL. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. *Mol Cell Biol.* 2005 Jan; 25(1):264-77. PMID: 15601848.

View in: [PubMed](#)

59. Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D₃-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D₃ in prostate cancer cells. *Clin Cancer Res.* 2004 Dec 01; 10(23):8018-27. PMID: 15585637.

View in: [PubMed](#)

60. Agoulnik IU, Tong XW, Fischer DC, Körner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. *J Clin Endocrinol Metab.* 2004 Dec; 89(12):6340-7. PMID: 15579801.

View in: [PubMed](#)

61. Narayanan R, Sepulveda VA, Falzon M, Weigel NL. The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. *J Biol Chem.* 2004 Nov 05; 279(45):47298-310. PMID: 15331595.

View in: [PubMed](#)

62. Narayanan R, Allen MR, Gaddy D, Bloomfield SA, Smith CL, Weigel NL. Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D₃ and its analog, seocalcitol (EB1089). *Bone.* 2004 Jul; 35(1):134-43. PMID: 15207749.

View in: [PubMed](#)

63. Murthy S, Weigel NL. 1alpha,25-dihydroxyvitamin D₃ induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. *Prostate.* 2004 May 15; 59(3):282-91. PMID: 15042604.

View in: [PubMed](#)

64. Stewart LV, Weigel NL. Vitamin D and prostate cancer. *Exp Biol Med (Maywood).* 2004 Apr; 229(4):277-84. PMID: 15044710.

View in: [PubMed](#)

65. Murthy S, Marcelli M, Weigel NL. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. *Prostate*. 2003 Sep 01; 56(4):293-304. PMID: 12858358.

View in: [PubMed](#)

66. Iyer D, Belaguli N, Flück M, Rowan BG, Wei L, Weigel NL, Booth FW, Epstein HF, Schwartz RJ, Balasubramanyam A. Novel phosphorylation target in the serum response factor MADS box regulates alpha-actin transcription. *Biochemistry*. 2003 Jun 24; 42(24):7477-86. PMID: 12809504.

View in: [PubMed](#)

67. Agoulnik IU, Krause WC, Bingman WE, Rahman HT, Amrikachi M, Ayala GE, Weigel NL. Repressors of androgen and progesterone receptor action. *J Biol Chem*. 2003 Aug 15; 278(33):31136-48. PMID: 12771131.

View in: [PubMed](#)

68. Bruckheimer EM, Spurges K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. *J Urol*. 2003 Apr; 169(4):1553-7. PMID: 12629413.

View in: [PubMed](#)

69. Lamb DJ, Puxeddu E, Malik N, Stenoien DL, Nigam R, Saleh GY, Mancini M, Weigel NL, Marcelli M. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. *J Androl*. 2003 Mar-Apr; 24(2):215-25. PMID: 12634308.

View in: [PubMed](#)

70. Coleman KM, Dutertre M, El-Ghabawny A, Rowan BG, Weigel NL, Smith CL. Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). *J Biol Chem*. 2003 Apr 11; 278(15):12834-45. PMID: 12566449.

View in: [PubMed](#)

71. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. *Endocrinology*. 2003 Jan; 144(1):50-60. PMID: 12488329.

View in: [PubMed](#)

72. James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. *Mol Endocrinol*. 2002 Dec; 16(12):2692-705. PMID: 12456791.

View in: [PubMed](#)

73. Galet C, Min L, Narayanan R, Kishi M, Weigel NL, Ascoli M. Identification of a transferable two-amino-acid motif (GT) present in the C-terminal tail of the human lutropin receptor that redirects internalized G protein-coupled receptors from a degradation to a recycling pathway. *Mol Endocrinol*. 2003 Mar; 17(3):411-22. PMID: 12554787.

View in: [PubMed](#)

74. Narayanan R, Smith CL, Weigel NL. Vector-averaged gravity-induced changes in cell signaling and vitamin D receptor activity in MG-63 cells are reversed by a 1,25-(OH)₂D₃ analog, EB1089. *Bone*. 2002 Sep; 31(3):381-8. PMID: 12231410.

View in: [PubMed](#)

75. Polek TC, Weigel NL. Vitamin D and prostate cancer. *J Androl*. 2002 Jan-Feb; 23(1):9-17. PMID: 11780928.

View in: [PubMed](#)

76. Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, Allegretto EA. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. *Prostate*. 2001 Nov 01; 49(3):224-33. PMID: 11746268.

View in: [PubMed](#)

77. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. *J Natl Cancer Inst*. 2001 Sep 05; 93(17):1314-24. PMID: 11535706.

View in: [PubMed](#)

78. Lamb DJ, Weigel NL, Marcelli M. Androgen receptors and their biology. *Vitam Horm*. 2001; 62:199-230. PMID: 11345899.

View in: [PubMed](#)

79. Knotts TA, Orkiszewski RS, Cook RG, Edwards DP, Weigel NL. Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. *J Biol Chem.* 2001 Mar 16; 276(11):8475-83. PMID: 11110801.

View in: [PubMed](#)

80. Rowan BG, Garrison N, Weigel NL, O'Malley BW. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. *Mol Cell Biol.* 2000 Dec; 20(23):8720-30. PMID: 11073973.

View in: [PubMed](#)

81. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. *Cancer Res.* 2000 Feb 15; 60(4):779-82. PMID: 10706079.

View in: [PubMed](#)

82. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. Androgen receptor mutations in prostate cancer. *Cancer Res.* 2000 Feb 15; 60(4):944-9. PMID: 10706109.

View in: [PubMed](#)

83. Rowan BG, Weigel NL, O'Malley BW. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. *J Biol Chem.* 2000 Feb 11; 275(6):4475-83. PMID: 10660621.

View in: [PubMed](#)

84. Clemm DL, Sherman L, Boonyaratanaakornkit V, Schrader WT, Weigel NL, Edwards DP. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. *Mol Endocrinol.* 2000 Jan; 14(1):52-65. PMID: 10628747.

View in: [PubMed](#)

85. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. *Endocrinology.* 2000 Jan; 141(1):10-7. PMID: 10614618.

View in: [PubMed](#)

86. Simeoni S, Mancini MA, Stenoien DL, Marcelli M, Weigel NL, Zanisi M, Martini L, Poletti A. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. *Hum Mol Genet*. 2000 Jan 01; 9(1):133-44. PMID: 10587588.

View in: [PubMed](#)

87. Nazareth LV, Stenoien DL, Bingman WE, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) *Mol Endocrinol*. 1999 Dec; 13(12):2065-75. PMID: 10598582.

View in: [PubMed](#)

88. Walker C, Ahmed SA, Brown T, Ho SM, Hodges L, Lucier G, Russo J, Weigel N, Weise T, Vandenberghe J. Species, interindividual, and tissue specificity in endocrine signaling. *Environ Health Perspect*. 1999 Aug; 107 Suppl 4:619-24. PMID: 10421772.

View in: [PubMed](#)

89. Labaree DC, Hoyte RM, Nazareth LV, Weigel NL, Hochberg RB. 7alpha-Iodo and 7alpha-fluoro steroids as androgen receptor-mediated imaging agents. *J Med Chem*. 1999 Jun 03; 42(11):2021-34. PMID: 10354410.

View in: [PubMed](#)

90. Blutt SE, Weigel NL. Vitamin D and prostate cancer. *Proc Soc Exp Biol Med*. 1999 Jun; 221(2):89-98. PMID: 10352118.

View in: [PubMed](#)

91. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. *Hum Mol Genet*. 1999 May; 8(5):731-41. PMID: 10196362.

View in: [PubMed](#)

92. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, Ingraham HA. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. *Mol Cell*. 1999 Apr; 3(4):521-6. PMID: 10230405.

View in: [PubMed](#)

93. Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. *J Mol Med (Berl)*. 1998 Jun; 76(7):469-79. PMID: 9660165.

View in: [PubMed](#)

94. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. *Mol Cell Biol*. 1998 Mar; 18(3):1369-78. PMID: 9488452.

View in: [PubMed](#)

95. Mangal RK, Wiegle RD, Poindexter AN, Weigel NL. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. *J Steroid Biochem Mol Biol*. 1997 Nov-Dec; 63(4-6):195-202. PMID: 9459185.

View in: [PubMed](#)

96. Zhang Y, Beck CA, Poletti A, Clement JP, Prendergast P, Yip TT, Hutchens TW, Edwards DP, Weigel NL. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. *Mol Endocrinol*. 1997 Jun; 11(6):823-32. PMID: 9171245.

View in: [PubMed](#)

97. Bai W, Rowan BG, Allgood VE, O'Malley BW, Weigel NL. Differential phosphorylation of chicken progesterone receptor in hormone-dependent and ligand-independent activation. *J Biol Chem*. 1997 Apr 18; 272(16):10457-63. PMID: 9099688.

View in: [PubMed](#)

98. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-dihydroxyvitamin D₃ and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. *Endocrinology*. 1997 Apr; 138(4):1491-7. PMID: 9075707.

View in: [PubMed](#)

99. Giffin W, Kwast-Welfeld J, Rodda DJ, Préfontaine GG, Traykova-Andonova M, Zhang Y, Weigel NL, Lefebvre YA, Haché RJ. Sequence-specific DNA binding and transcription factor phosphorylation by Ku Autoantigen/DNA-dependent protein kinase. Phosphorylation of Ser-527 of the rat glucocorticoid receptor. *J Biol Chem*. 1997 Feb 28; 272(9):5647-58. PMID: 9038175.

View in: [PubMed](#)

100. Allgood VE, Zhang Y, O'Malley BW, Weigel NL. Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high-efficiency DNA transfer. *Biochemistry*. 1997 Jan 07; 36(1):224-32. PMID: 8993337.

View in: [PubMed](#)

101. Weigel NL. Steroid hormone receptors and their regulation by phosphorylation. *Biochem J*. 1996 Nov 01; 319 (Pt 3):657-67. PMID: 8920964.

View in: [PubMed](#)

102. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. *J Biol Chem*. 1996 Aug 16; 271(33):19900-7. PMID: 8702703.

View in: [PubMed](#)

103. Beck CA, Zhang Y, Altmann M, Weigel NL, Edwards DP. Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. *J Biol Chem*. 1996 Aug 09; 271(32):19546-55. PMID: 8702648.

View in: [PubMed](#)

104. Bai W, Weigel NL. Phosphorylation of Ser211 in the chicken progesterone receptor modulates its transcriptional activity. *J Biol Chem*. 1996 May 31; 271(22):12801-6. PMID: 8662804.

View in: [PubMed](#)

105. Beck CA, Zhang Y, Weigel NL, Edwards DP. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. *J Biol Chem*. 1996 Jan 12; 271(2):1209-17. PMID: 8557652.

View in: [PubMed](#)

106. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. *Mol Endocrinol*. 1995 Aug; 9(8):1029-40. PMID: 7476977.

View in: [PubMed](#)

107. Edwards DP, Altmann M, DeMarzo A, Zhang Y, Weigel NL, Beck CA. Progesterone receptor and the mechanism of action of progesterone antagonists. *J Steroid Biochem Mol Biol*. 1995 Jun; 53(1-6):449-58. PMID: 7626494.

View in: [PubMed](#)

108. Weigel NL, Bai W, Zhang Y, Beck CA, Edwards DP, Poletti A. Phosphorylation and progesterone receptor function. *J Steroid Biochem Mol Biol.* 1995 Jun; 53(1-6):509-14. PMID: 7626502.

View in: [PubMed](#)

109. Bai W, Weigel NL. Phosphorylation and steroid hormone action. *Vitam Horm.* 1995; 51:289-313. PMID: 7483325.

View in: [PubMed](#)

110. O'Malley BW, Schrader WT, Mani S, Smith C, Weigel NL, Conneely OM, Clark JH. An alternative ligand-independent pathway for activation of steroid receptors. *Recent Prog Horm Res.* 1995; 50:333-47. PMID: 7740165.

View in: [PubMed](#)

111. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. *J Biol Chem.* 1994 Dec 09; 269(49):31034-40. PMID: 7983041.

View in: [PubMed](#)

112. Bai W, Tullos S, Weigel NL. Phosphorylation of Ser530 facilitates hormone-dependent transcriptional activation of the chicken progesterone receptor. *Mol Endocrinol.* 1994 Nov; 8(11):1465-73. PMID: 7877616.

View in: [PubMed](#)

113. Zhang Y, Bai W, Allgood VE, Weigel NL. Multiple signaling pathways activate the chicken progesterone receptor. *Mol Endocrinol.* 1994 May; 8(5):577-84. PMID: 8058067.

View in: [PubMed](#)

114. Hilliard GM, Cook RG, Weigel NL, Pike JW. 1,25-dihydroxyvitamin D₃ modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. *Biochemistry.* 1994 Apr 12; 33(14):4300-11. PMID: 8155647.

View in: [PubMed](#)

115. Poletti A, Conneely OM, McDonnell DP, Schrader WT, O'Malley BW, Weigel NL. Chicken progesterone receptor expressed in *Saccharomyces cerevisiae* is correctly phosphorylated at all four Ser-Pro phosphorylation sites. *Biochemistry*. 1993 Sep 21; 32(37):9563-9. PMID: 8373763.

View in: [PubMed](#)

116. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. *Proc Natl Acad Sci U S A*. 1993 May 15; 90(10):4441-5. PMID: 8389450.

View in: [PubMed](#)

117. Poletti A, Weigel NL. Identification of a hormone-dependent phosphorylation site adjacent to the DNA-binding domain of the chicken progesterone receptor. *Mol Endocrinol*. 1993 Feb; 7(2):241-6. PMID: 8469237.

View in: [PubMed](#)

118. Edwards DP, Weigel NL, Nordeen SK, Beck CA. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. *Breast Cancer Res Treat*. 1993; 27(1-2):41-56. PMID: 8260729.

View in: [PubMed](#)

119. Weigel NL, Beck CA, Estes PA, Prendergast P, Altmann M, Christensen K, Edwards DP. Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. *Mol Endocrinol*. 1992 Oct; 6(10):1585-97. PMID: 1448113.

View in: [PubMed](#)

120. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai MJ, O'Malley BW. Hormone and anti-hormone induce distinct conformational changes which are central to steroid receptor activation. *J Biol Chem*. 1992 Sep 25; 267(27):19513-20. PMID: 1326555.

View in: [PubMed](#)

121. Poletti A, Weigel NL, McDonnell DP, Schrader WT, O'Malley BW, Conneely OM. A novel, highly regulated, rapidly inducible system for the expression of chicken progesterone receptor, cPRA, in *Saccharomyces cerevisiae*. *Gene*. 1992 May 01; 114(1):51-8. PMID: 1316867.

View in: [PubMed](#)

122. Beck CA, Weigel NL, Edwards DP. Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors. *Mol Endocrinol*. 1992 Apr; 6(4):607-20. PMID: 1316549.

View in: [PubMed](#)

123. Weigel NL, Carter TH, Schrader WT, O'Malley BW. Chicken progesterone receptor is phosphorylated by a DNA-dependent protein kinase during in vitro transcription assays. *Mol Endocrinol*. 1992 Jan; 6(1):8-14. PMID: 1738374.

View in: [PubMed](#)

124. McDonnell DP, Nawaz Z, Densmore C, Weigel NL, Pham TA, Clark JH, O'Malley BW. High level expression of biologically active estrogen receptor in *Saccharomyces cerevisiae*. *J Steroid Biochem Mol Biol*. 1991 Sep; 39(3):291-7. PMID: 1911419.

View in: [PubMed](#)

125. Allan GF, Ing NH, Tsai SY, Srinivasan G, Weigel NL, Thompson EB, Tsai MJ, O'Malley BW. Synergism between steroid response and promoter elements during cell-free transcription. *J Biol Chem*. 1991 Mar 25; 266(9):5905-10. PMID: 2005127.

View in: [PubMed](#)

126. O'Malley BW, Tsai SY, Bagchi M, Weigel NL, Schrader WT, Tsai MJ. Molecular mechanism of action of a steroid hormone receptor. *Recent Prog Horm Res*. 1991; 47:1-24; discussion 24-6. PMID: 1745818.

View in: [PubMed](#)

127. Denner LA, Weigel NL, Maxwell BL, Schrader WT, O'Malley BW. Regulation of progesterone receptor-mediated transcription by phosphorylation. *Science*. 1990 Dec 21; 250(4988):1740-3. PMID: 2176746.

View in: [PubMed](#)

128. Rodriguez R, Weigel NL, O'Malley BW, Schrader WT. Dimerization of the chicken progesterone receptor in vitro can occur in the absence of hormone and DNA. *Mol Endocrinol*. 1990 Dec; 4(12):1782-90. PMID: 2082181.

View in: [PubMed](#)

129. Denner LA, Schrader WT, O'Malley BW, Weigel NL. Hormonal regulation and identification of chicken progesterone receptor phosphorylation sites. *J Biol Chem.* 1990 Sep 25; 265(27):16548-55. PMID: 2398063.

View in: [PubMed](#)

130. Schweers LA, Frank DE, Weigel NL, Sanders MM. The steroid-dependent regulatory element in the ovalbumin gene does not function as a typical steroid response element. *J Biol Chem.* 1990 May 05; 265(13):7590-5. PMID: 2332444.

View in: [PubMed](#)

131. Bagchi MK, Tsai SY, Weigel NL, Tsai MJ, O'Malley BW. Regulation of in vitro transcription by progesterone receptor. Characterization and kinetic studies. *J Biol Chem.* 1990 Mar 25; 265(9):5129-34. PMID: 2318886.

View in: [PubMed](#)

132. Klein-Hitpass L, Tsai SY, Weigel NL, Allan GF, Riley D, Rodriguez R, Schrader WT, Tsai MJ, O'Malley BW. The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex. *Cell.* 1990 Jan 26; 60(2):247-57. PMID: 2153462.

View in: [PubMed](#)

133. Mak P, McDonnell DP, Weigel NL, Schrader WT, O'Malley BW. Expression of functional chicken oviduct progesterone receptors in yeast (*Saccharomyces cerevisiae*). *J Biol Chem.* 1989 Dec 25; 264(36):21613-8. PMID: 2689442.

View in: [PubMed](#)

134. Denner LA, Weigel NL, Schrader WT, O'Malley BW. Hormone-dependent regulation of chicken progesterone receptor deoxyribonucleic acid binding and phosphorylation. *Endocrinology.* 1989 Dec; 125(6):3051-8. PMID: 2583054.

View in: [PubMed](#)

135. Weigel NL, Schrader WT, O'Malley BW. Antibodies to chicken progesterone receptor peptide 523-536 recognize a site exposed in receptor-deoxyribonucleic acid complexes but not in receptor-heat shock protein-90 complexes. *Endocrinology.* 1989 Nov; 125(5):2494-501. PMID: 2791998.

View in: [PubMed](#)

136. Rodriguez R, Carson MA, Weigel NL, O'Malley BW, Schrader WT. Hormone-induced changes in the in vitro DNA-binding activity of the chicken progesterone receptor. *Mol Endocrinol*. 1989 Feb; 3(2):356-62. PMID: 2710137.

View in: [PubMed](#)

137. Tsai SY, Carlstedt-Duke J, Weigel NL, Dahlman K, Gustafsson JA, Tsai MJ, O'Malley BW. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. *Cell*. 1988 Oct 21; 55(2):361-9. PMID: 3167984.

View in: [PubMed](#)

138. Denner LA, Weigel NL, Schrader WT, O'Malley BW. High-yield high-performance liquid chromatographic analysis of steroid hormone receptors on glass columns. *Anal Biochem*. 1987 Mar; 161(2):291-9. PMID: 3578794.

View in: [PubMed](#)

139. Denner LA, Bingman WE, Greene GL, Weigel NL. Phosphorylation of the chicken progesterone receptor. *J Steroid Biochem*. 1987; 27(1-3):235-43. PMID: 3695483.

View in: [PubMed](#)

140. Kulomaa MS, Weigel NL, Kleinsek DA, Beattie WG, Conneely OM, March C, Zarucki-Schulz T, Schrader WT, O'Malley BW. Amino acid sequence of a chicken heat shock protein derived from the complementary DNA nucleotide sequence. *Biochemistry*. 1986 Oct 07; 25(20):6244-51. PMID: 3024703.

View in: [PubMed](#)

141. Zarucki-Schulz T, Kulomaa MS, Headon DR, Weigel NL, Baez M, Edwards DP, McGuire WL, Schrader WT, O'Malley BW. Molecular cloning of a cDNA for the chicken progesterone receptor B antigen. *Proc Natl Acad Sci U S A*. 1984 Oct; 81(20):6358-62. PMID: 6593705.

View in: [PubMed](#)

142. Edwards DP, Weigel NL, Schrader WT, O'Malley BW, McGuire WL. Structural analysis of chicken oviduct progesterone receptor using monoclonal antibodies to the subunit B protein. *Biochemistry*. 1984 Sep 11; 23(19):4427-35. PMID: 6207857.

View in: [PubMed](#)

143. Dicker PD, Tsai SY, Weigel NL, Tsai MJ, Schrader WT, O'Malley BW. Monoclonal antibody to the hen oviduct progesterone receptor produced following in vitro immunization. *J Steroid Biochem.* 1984 Jan; 20(1):43-50. PMID: 6538613.
View in: [PubMed](#)
144. Grill H, Weigel N, Gaffney BJ, Roseman S. Sugar transport by the bacterial phosphotransferase system. Radioactive and electron paramagnetic resonance labeling of the *Salmonella typhimurium* phosphocarrier protein (HPr) at the NH₂-terminal methionine. *J Biol Chem.* 1982 Dec 10; 257(23):14510-7. PMID: 6292226.
View in: [PubMed](#)
145. Weigel N, Waygood EB, Kukuruzinska MA, Nakazawa A, Roseman S. Sugar transport by the bacterial phosphotransferase system. Isolation and characterization of enzyme I from *Salmonella typhimurium*. *J Biol Chem.* 1982 Dec 10; 257(23):14461-9. PMID: 6754728.
View in: [PubMed](#)
146. Beneski DA, Nakazawa A, Weigel N, Hartman PE, Roseman S. Sugar transport by the bacterial phosphotransferase system. Isolation and characterization of a phosphocarrier protein HPr from wild type and mutants of *Salmonella typhimurium*. *J Biol Chem.* 1982 Dec 10; 257(23):14492-8. PMID: 6754731.
View in: [PubMed](#)
147. Weigel N, Powers DA, Roseman S. Sugar transport by the bacterial phosphotransferase system. Primary structure and active site of a general phosphocarrier protein (HPr) from *Salmonella typhimurium*. *J Biol Chem.* 1982 Dec 10; 257(23):14499-509. PMID: 6754732.
View in: [PubMed](#)
148. Weigel N, Kukuruzinska MA, Nakazawa A, Waygood EB, Roseman S. Sugar transport by the bacterial phosphotransferase system. Phosphoryl transfer reactions catalyzed by enzyme I of *Salmonella typhimurium*. *J Biol Chem.* 1982 Dec 10; 257(23):14477-91. PMID: 6754730.
View in: [PubMed](#)
149. Kukuruzinska MA, Weigel N, Waygood EB. Enzyme I from salmonella typhimurium. *Methods Enzymol.* 1982; 90 Pt E:431-6. PMID: 6759860.
View in: [PubMed](#)

150. Nakazawa A, Weigel N. HPr from *Salmonella typhimurium*. *Methods Enzymol.* 1982; 90 Pt E:436-9. PMID: 6759861.

View in: [PubMed](#)

151. Weigel NL, Pousette A, Schrader WT, O'Malley BW. Analysis of chicken progesterone receptor structure using a spontaneous sheep antibody. *Biochemistry*. 1981 Nov 24; 20(24):6798-803. PMID: 7317354.

View in: [PubMed](#)

152. Weigel NL, Tash JS, Means AR, Schrader WT, O'Malley BW. Phosphorylation of hen progesterone receptor by cAMP dependent protein kinase. *Biochem Biophys Res Commun*. 1981 Sep 16; 102(1):513-9. PMID: 6272798.

View in: [PubMed](#)

153. Schrader WT, Birnbaumer ME, Hughes MR, Weigel NL, Grody WW, O'Malley BW. Studies on the structure and function of the chicken progesterone receptor. *Recent Prog Horm Res*. 1981; 37:583-633. PMID: 7025136.

View in: [PubMed](#)

154. Anderson B, Weigel N, Kundig W, Roseman S. Sugar transport. 3. Purification and properties of a phosphocarrier protein (HPr) of the phosphoenolpyruvate-dependent phosphotransferase system of *Escherichia coli*. *J Biol Chem*. 1971 Nov 25; 246(22):7023-33. PMID: 4942330.

View in: [PubMed](#)